Illnesses like high blood pressure, diabetes, and glaucoma have hardly any symptoms before the damage has been done. Here, ...

Key Points Revenue (GAAP) totaled $38,000 in Q1 2025. Net loss (GAAP) improved to $8.0 million in Q2 2025, with earnings per share (GAAP) at ($0.16) in Q2 2025 versus ($0.25) GAAP net loss per share ...

4. Avoid High-Strain Activities Initially: Isometric exercises like heavy weightlifting, holding planks, or pushing through ...

Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November.

During National Wellness Month, the American Red Cross encourages people to prioritize their personal health and well-being while helping to save lives with a blood or platelet donation. Donors of all ...

August is National Wellness Month and the American Red Cross is encouraging people to prioritize their health and well being ...

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

Exact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests. Continue reading this article with a Barron’ ...

Red blood cells, long thought to be passive bystanders in the formation of blood clots, actually play an active role in ...

Exact Sciences stock crashed Wednesday after the company inked a deal for the exclusive eights to Freenome's blood-based ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...